

## THE CLINICAL PICTURE

**SUDIP KUMAR GHOSH, MD, DNB**

Assistant Professor, Department of Dermatology, Venereology, and Leprosy, R. G. Kar Medical College, Kolkata, India

**DEBABRATA BANDYOPADHYAY, MD**

Professor, Department of Dermatology, Venereology, and Leprosy, Calcutta Medical College, Kolkata, India

**LOKNATH GHOSHAL, MD**


Resident Medical Officer-Cum-Clinical Tutor, Department of Dermatology, Venereology, and Leprosy, R. G. Kar Medical College, Kolkata, India

# The Clinical Picture

## Painful red hands and feet



**FIGURE 1.** Erythema of both hands.



**FIGURE 2.** Blanching of erythema with pressure.

**A** 42-YEAR-OLD BUSINESSMAN PRESENTED with recurrent redness, swelling, warmth, and burning pain on both hands and both feet for the preceding year (**FIGURE 1**). His symptoms were worse during heat exposure or physical effort and were relieved by immersing his hands and feet in cold water and by elevating his limbs. He had no other local or systemic symptoms, and he had not been on any medications. His medical history was noncontributory, and there was no family history of similar illness.

The erythema blanched when pressure was applied (**FIGURE 2**). The affected areas were slightly tender. Other areas of his skin and

mucosae were normal. Neurologic examination and examination of other systems were normal. Results of laboratory testing (complete blood cell count, biochemistry panel, antinuclear antibody test) and gastrointestinal endoscopy were normal.

**Q:** What is the diagnosis?

- Fabry disease
- Peripheral neuropathy
- Polycythemia
- Primary idiopathic erythromelalgia
- Erythrodysesthesia syndrome

**A:** The correct diagnosis is primary idiopathic erythromelalgia.

Erythromelalgia is a relatively rare clinical

doi:10.3949/ccjm.79a.11052

condition of uncertain etiology, characterized by the triad of episodic redness, warmth, and burning pain in the extremities.<sup>1,2</sup>

The condition has primary (ie, no underlying cause is found) and secondary forms.<sup>1,3</sup> The primary form may be inherited in an autosomal dominant manner (in which case the symptoms begin in childhood), or it may be idiopathic.<sup>4</sup> On the other hand, erythromelalgia can also be secondary to polycythemia vera and other myeloproliferative disorders, connective tissue disorders, neuropathies, spinal cord diseases, carcinoma of the colon and thyroid, and astrocytomas.<sup>1-6</sup>

The common pathologic mechanism of erythromelalgia is thought to be microvascular arteriovenous shunting.<sup>5</sup> A mutation in the voltage-gated sodium channel alpha subunit  $Na_v1.7$  may result in primary erythromelalgia. Small-fiber neuropathy<sup>2</sup> can manifest as erythromelalgia and may respond to steroids.

The symptoms can be intermittent or, in rare cases, constant.<sup>3</sup> The lower limbs are more commonly involved than the upper ones.<sup>3</sup> Involvement is often bilateral and symmetric.<sup>3</sup> The symptoms may worsen at night, after alcohol consumption, with higher environmental temperature, and with moderate exercise.<sup>3</sup> In rare cases, ulceration and gangrene may occur. Patients may get relief by cooling the affected areas.<sup>2</sup>

### ■ DIAGNOSIS BY EXCLUSION OR BASED ON THE PRESENTATION

The diagnosis of erythromelalgia is based on a detailed history and physical examination during a painful episode.<sup>2,3</sup> Because the condition is intermittent, only about two-thirds of patients have abnormal findings on physical examination at the time of presentation; in such cases, the diagnosis is based on the history alone.<sup>2</sup>

Testing is needed to exclude other diagnoses and to determine the cause of secondary erythromelalgia. Histopathologic study of lesions is not helpful, as the features are nonspecific and hence nondiagnostic.<sup>2</sup>

In our patient, the typical clinical features and the lack of an obvious cause on diagnostic testing confirmed the diagnosis.

### ■ THE DIFFERENTIAL DIAGNOSIS

Other conditions can be ruled out by clinical features and laboratory testing.

**Fabry disease** causes paresthesia and burning pain in the extremities but not erythema. Characteristic dark red keratotic papules are seen all over the body (angiokeratoma corporis diffusum). It is often associated with progressive renal insufficiency.

**Peripheral neuropathy** of varying causes may also cause pain in the extremities but not erythema. Neurologic examination and a nerve conduction velocity study can resolve the diagnostic problem. Clinical features and laboratory testing often help to pinpoint the cause of neuropathy.

**Polycythemia** may cause erythema in the hands, feet, and face and mucosal engorgement. Telangiectasia, petechiae, and cyanosis may also occur. Our patient's normal complete blood cell count excluded this condition.

**Erythrodysesthesia syndrome**, typically caused by chemotherapeutic drugs, was not included in the differential diagnosis since our patient had taken no medications.

Other causes of palmar erythema to rule out, depending on the patient's presentation, may include thyrotoxicosis, chronic febrile illness, leukemia, hepatic insufficiency, chronic alcoholism, and rheumatoid arthritis.

### ■ TREATMENT AND PROGNOSIS

There is no definitive therapy for erythromelalgia.<sup>4</sup> Treatment is often difficult and needs a multidisciplinary approach. Simple measures such as cooling<sup>2</sup> (eg, applying cold towels, immersion in cool water, walking on cold floors) or elevating the affected extremity often relieve symptoms. Patients should avoid precipitating factors such as warmth, dependency of extremities, exercise, tight footwear, and alcohol intake.

If there is an underlying disease, treating the disease may also alleviate the symptoms.<sup>7</sup> Aspirin<sup>2,7</sup> is the therapy of choice for erythromelalgia in patients with an underlying myeloproliferative disorder, and some authors have advocated it for all patients with erythromelalgia unless there is a contraindication.<sup>7</sup>

Other possible first-line treatments include

**Only two-thirds of patients have abnormal findings on physical examination at presentation**

the synthetic prostaglandin E<sub>1</sub> analogue misoprostol (Cytotec) and prostacyclins. Gabapentin (Neurontin), serotonin reuptake inhibitors such as sertraline (Zoloft) and venlafaxine (Effexor), and intravenous nitroprusside (Nitropress) are considered second-line drugs.<sup>7</sup>

Surgical sympathectomy<sup>8</sup> has also been tried, with variable results.

### Outcomes in patients with erythromelalgia

In a case series from Mayo Clinic,<sup>2</sup> approximately equal numbers of patients with erythromelalgia became worse, stayed the same, or got better, and the disease resolved in 10% over a mean of 8.7 years.

### ■ THE OUTCOME IN OUR PATIENT

We advised our patient to avoid strenuous activity in a warm environment and to work in cooler areas as much as possible. We told him to wrap his affected extremities with cold towels during attacks, and we prescribed aspirin (650 mg/day) for 3 months. The treatment did not cure his condition, but his symptoms lessened within 2 months. We later referred him to a pain clinic.

### ■ REFERENCES

1. **Kalgaard OM, Seem E, Kvernebo K.** Erythromelalgia: a clinical study of 87 cases. *Intern Med* 1997; 242:191–197.
2. **Davis MD, O’Fallon WM, Rogers RS 3rd, Rooke TW.** Natural history of erythromelalgia: presentation and outcome in 168 patients. *Arch Dermatol* 2000; 136:330–336.
3. **Galimberti D, Pontón A, Rubio L, et al.** A case of primary erythromelalgia. *J Eur Acad Dermatol Venereol* 2009; 23:1338–1339.
4. **Ljubojevic S, Lipozencic J, Pustisek N.** Erythromelalgia. *Acta Dermatovenerol Croat* 2004; 12:99–105.
5. **Mørk C, Kvernebo K, Asker CL, Salerud EG.** Reduced skin capillary density during attacks of erythromelalgia implies arteriovenous shunting as pathogenetic mechanism. *J Invest Dermatol* 2002; 119:949–953.
6. **James WD, Berger TG, Elston DM.** *Andrews’ Diseases of the Skin: Clinical Dermatology*. 10th ed. Philadelphia, PA: Saunders Elsevier; 2006.
7. **Mørk C, Kvernebo K.** Erythromelalgia. In: Lebowitz MG, Heymann WR, Berth-Jones J, Koulson Y. editors. *Treatment of Skin Disease: Comprehensive Therapeutic Strategies*. 3rd ed. Philadelphia, PA: Saunders Elsevier; 2010:236–238.
8. **Seishima M, Kanoh H, Izumi T, et al.** A refractory case of secondary erythromelalgia successfully treated with lumbar sympathetic ganglion block. *Br J Dermatol* 2000; 143:868–872.

**ADDRESS:** Sudip Kumar Ghosh, MD, DNB, Department of Dermatology, Venereology, and Leprosy, R. G. Kar Medical College, 1, Khudiram Bose Road, Kolkata 700004, West Bengal, India; e-mail [dr\\_skgghosh@yahoo.co.in](mailto:dr_skgghosh@yahoo.co.in).